{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:02:47Z","timestamp":1772802167071,"version":"3.50.1"},"reference-count":38,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1536\/ihj.14-034","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T23:09:48Z","timestamp":1413241788000},"page":"519-525","source":"Crossref","is-referenced-by-count":9,"title":["Effects of the T\/L-type Calcium Channel Blocker Benidipine on Albuminuria and Plasma Aldosterone Concentration"],"prefix":"10.1536","volume":"55","author":[{"given":"Shigemasa","family":"Tani","sequence":"first","affiliation":[{"name":"Department of Cardiology, Surugadai Nihon University Hospital"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Surugadai Nihon University Hospital"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Surugadai Nihon University Hospital"},{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Nihon University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003; 83: 117-61. (Review)","DOI":"10.1152\/physrev.00018.2002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jones SW. Overview of voltage-dependent calcium channels. J Bioenerg Biomembr 1998; 30: 299-312. (Review)","DOI":"10.1023\/A:1021977304001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hayashi K, Homma K, Wakino S, <i>et al<\/i>. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med 2010; 59: 84-95. (Review)","DOI":"10.2302\/kjm.59.84"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Rossier MF, Burnay MM, Vallotton MB, Capponi AM. Distinct functions of T- and L-type calcium channels during activation of bovine adrenal glomerulosa cells. Endocrinology 1996; 137: 4817-26.","DOI":"10.1210\/endo.137.11.8895352"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-70. (Review)","DOI":"10.1016\/j.cardiores.2003.11.037"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Akizuki O, Inayoshi A, Kitayama T, <i>et al<\/i>. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in humanadrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584: 424-34.","DOI":"10.1016\/j.ejphar.2008.02.001"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yamamoto E, Kataoka K, Dong YF, <i>et al<\/i>. Benidipine, a dihydropyridine L-type\/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats. J Hypertens 2010; 28: 1321-9.","DOI":"10.1097\/HJH.0b013e3283388045"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kosaka H, Hirayama K, Yoda N, <i>et al<\/i>. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 2010; 635: 49-55.","DOI":"10.1016\/j.ejphar.2010.03.018"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ogihara T, Kikuchi K, Matsuoka H, <i>et al<\/i>. Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.","DOI":"10.1038\/hr.2009.34"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Matsuo S, Imai E, Horio M, <i>et al<\/i>; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-92.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Furukawa T, Nukada T, Namiki Y, <i>et al<\/i>. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3(alpha(1I))) expressed in Xenopus oocytes. Eur J Pharmacol 2009; 613: 100-7.","DOI":"10.1016\/j.ejphar.2009.04.036"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32: 270-5.","DOI":"10.1038\/hr.2009.11"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fujita T, Ando K, Nishimura H, <i>et al<\/i>; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease (CARTER) Study Investigators. Antiproteinuria effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-9.","DOI":"10.1038\/sj.ki.5002623"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ishimitsu T, Kameda T, Akashiba A, <i>et al<\/i>. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-6.","DOI":"10.1291\/hypres.30.621"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura T, Sugaya T, Kawagoe Y, <i>et al<\/i>. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321-6.","DOI":"10.1097\/MAJ.0b013e318065c254"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011; 32: 2739-47. (Review)","DOI":"10.1093\/eurheartj\/ehr253"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Abe M, Okada K, Maruyama N, <i>et al<\/i>. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268-73.","DOI":"10.1038\/hr.2010.221"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sarnak MJ, Levey AS, Schoolwerth AC, <i>et al<\/i>; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69. (Review)","DOI":"10.1161\/01.CIR.0000095676.90936.80"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Vasan RS, Evans JC, Larson MG, <i>et al<\/i>. Serum aldosterone and the incidence of hypertension in non-hypertensive persons. N Engl J Med 2004; 351: 33-41.","DOI":"10.1056\/NEJMoa033263"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Blood Pressure Lowering Treatment Trialists\u2019 Collaboration, Turnbull F, Neal B, Pfeffer M, <i>et al<\/i>. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-8.","DOI":"10.1097\/HJH.0b013e3280bad9b4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23: 1917-28. (Review)","DOI":"10.1681\/ASN.2012040390"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10: 1-8.","DOI":"10.1016\/S0895-7061(96)00301-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Beygui F, Collet JP, Benoliel JJ, <i>et al<\/i>. High plasma aldosterone levels on admission are associated with death in patients presenting with acute STelevation myocardial infarction. Circulation 2006; 114: 2604-10.2","DOI":"10.1161\/CIRCULATIONAHA.106.634626"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. G\u00fcder G, Bauersachs J, Frantz S, <i>et al<\/i>. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115: 1754-61.","DOI":"10.1161\/CIRCULATIONAHA.106.653964"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Duprez DA, Bauwens FR, De Buyzere ML, <i>et al<\/i>. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993; 71: 17A-20A.","DOI":"10.1016\/0002-9149(93)90240-D"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131: 453-9.","DOI":"10.1378\/chest.06-1442"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, <i>et al<\/i>. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21: 10-3.","DOI":"10.1038\/ajh.2007.15"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Williams GH, Burgess E, Kolloch RE, <i>et al<\/i>. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990-6.","DOI":"10.1016\/j.amjcard.2004.01.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.","DOI":"10.1053\/j.ajkd.2005.03.007"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Persson F, Lewis JB, Lewis EJ, <i>et al<\/i>. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010; 33: 2304-9.","DOI":"10.2337\/dc10-0833"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-63.","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"33","unstructured":"33. Evidence-based Clinical Practice Guideline for CKD 2013. The Japanese Society of Nephrology. Available at: http:\/\/www.jsn.or.jp\/guideline\/pdf\/ CKD_evidence2013\/all.pdf (Japanese). Accessed July 16, 2014."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Cohn JN, Anand IS, Latini R, <i>et al<\/i>; Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306-9.","DOI":"10.1161\/01.CIR.0000091234.45664.62"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Matsuzaki M, Ogihara T, Umemoto S, <i>et al<\/i>; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649-59.","DOI":"10.1097\/HJH.0b013e328348345d"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Rakugi H, Ogihara T, Umemoto S, <i>et al<\/i>; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res 2013; 36: 947-58.","DOI":"10.1038\/hr.2013.63"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Tani S, Nagao K, Anazawa T, <i>et al<\/i>. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study. J Cardiovasc Pharmacol 2008; 52: 28-34.","DOI":"10.1097\/FJC.0b013e31817d4507"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Nishigaki K, Inoue Y, Yamanouchi Y, <i>et al<\/i>. Prognostic effects of calcium channel blockers in patients with vasospastic angina--a meta-analysis. Circ J 2010; 74: 1943-50.","DOI":"10.1253\/circj.CJ-10-0292"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/6\/55_14-034\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:43:53Z","timestamp":1618616633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/6\/55_14-034\/_article"}},"subtitle":["A Pilot Study Involving Switching from L-type Calcium Channel Blockers to Benidipine"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.14-034","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}